Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia
Authors:
Z. Kořístek 1; P. Žák 2
Authors place of work:
Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc.
1; Oddělení klinické hematologie II. interní kliniky Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.
2
Published in the journal:
Vnitř Lék 2008; 54(7-8): 745-750
Category:
Review
Summary
Two main causes of early mortality of acute promyelocytic leukemia (APL) are rewieved, unique type of coagulopathy typical for APL and differentiation syndrome sometimes complicating treatment of APL with all‑trans retinoic acid (ATRA) or arsenic trioxide (ATO). The information covers analysis of the patophysiologies of both conditions and also recommendations considering treatments and preventive measures.
Key words:
acute promyelocytic leukemia – differentiation syndrome – RAS – ATRA syndrome – ATO syndrome – coagulopathy – annexin II – hyperfibrinolysis
Zdroje
1. Castaigne S, Chomienne C, Daniel MT et al. All‑trans retinoic acid as a differentiation therapy of acute promyelocytic leukemia. I. Clinical Results. Blood 1990; 76: 1704–1709.
2. Frankel SR, Eardley A, Lauwers G et al. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292–296.
3. Frankel SR, Eardley A, Heller G et al. All‑trans retinoic acid for acute promyelocytic leukemia. Results of the New York study. Ann Intern Med 1994; 120: 278–286.
4. Fenaux P, Le Deley MC, Castaigne S et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82: 3241–3249.
5. Vahdat L, Maslak P, Miller WH et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low‑dose chemotherapy, PML/RAR-α isoform, and CD13 express-ion in patients treated with all‑trans retinoic acid. Blood 1994; 84: 3843–3849.
6. De Botton S, Dombret H, Sanz M et al. Incidence, clinical features, and outcome of all trans‑retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998; 92: 2712–2718.
7. Tallman MS, Andersen JW, Schiffer CA et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoid acid syndrome. Blood 2000; 95: 90–95.
8. Matikainen S, Tapiovaara H, Vaheri A et al. Activation of interleukin-1 beta gene expression during retinoic acid‑induced granulocytic differentiation of promyeloid leukemia cells. Cell Growth Differ 1994; 5: 975–982.
9. Di Noto R, Schiavone EM, Ferrara F et al. All‑trans retinoic acid promotes a differential regulation of adhesion molecules on acute myeloid leukemia blast cells. Br J Haematol 1994; 88: 247–255.
10. Cavenagh JD, Gordon-Smith EC, Gibson FM et al. Acute myeloid leukemia blast cells bind to human endothelium in vitro utilizing E-selectin and vascular cell adhesion molecule-1 (VCAM‑1). Br J Haematol 1993; 85: 285–291.
11. Stucki A, Rivier AS, Gikic M et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001; 97: 2121–2129.
12. Steeber DA, Tang ML, Green NE et al. Leukocyte entry into sites of inflammation requires overlapping interactions between the L-selectin and ICAM‑1 pathways. J Immunol 1999; 163: 2176–2186.
13. Rodriguez-Cimadevilla JC, Beauchemin V, Villeneuve L et al. Coordinate secretion of interleukin-1 beta and granulocyte-macrophage colony-stimulating factor by the blast cells of acute myeloblastic leukemia: role of interleukin-1 as an endogenous inducer. Blood 1990; 76: 1481–1489.
14. Oster W, Cicco NA, Klein H et al. Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest 1989; 84: 451–457.
15. Delwel R, van Buitenen C, Salem M et al. Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release. Blood 1989; 74: 586–593.
16. Sanz MA, Martín G, González M et al. Risk-adapted treatment of acute promyelocytic leukemia with all‑trans‑retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237–1243.
17. Didisheim P, Trombold JS, Vandervoort LE et al. Acute promyelocytic leukemia with fibrinogen and factor V deficiencies. Blood 1964; 23: 717–728.
18. Drapkin RL, Gee TS, Dowling MD et al. Prophylactic heparin therapy in acute promyelocytic leukemia. Cancer 1978; 41: 2484–2490.
19. Cordonnier C, Vernant JP, Brun B et al. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985; 55: 18–25.
20. Rodeghiero F, Avvisati G, Castaman G et al. Early deaths and anti‑hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 2112–2117.
21. Goldberg MA, Ginsburg D, Mayer RJ et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 1987; 69: 187–191.
22. Keane TJ, Gorman AM, O’Connell LG et al. Epsilon-amino-caproic acid in the management of acute promyelocytic leu-kaemia. Acta Haematol 1976; 56: 202–204.
23. Avvisati G, ten Cate JW, Büller HR et al. Tranexamic acid for control of haemorr-hage in acute promyelocytic leukaemia. Lancet 1989; 2: 122–124.
24. Hoyle CF, Swirsky DM, Freedman L et al. Beneficial effect of heparin in the management of patients with APL. Br J Haematol 1988; 68: 283–289.
25. Gralnick HR, Abrell E. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia. Br J Haematol 1973; 24: 89–99.
26. Bauer KA, Rosenberg RD. Thrombin generation in acute promyelocytic leukemia. Blood 1984; 64: 791–796.
27. Bennett M, Parker AC, Ludlam CA. Platelet and fibrinogen survival in acute promyelocytic leukemia. Brit Med J 1976; 2: 565.
28. Avvisati G, ten Cate JW, Sturk A et al. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol 1988; 70: 43–48.
29. Sakata Y, Murakami T, Noro A et al. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991; 77: 1949–1957.
30. Sterrenberg L, Haak HL, Brommer EJ et al. Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia. Haemostasis 1985; 15: 126–133.
31. Imaoka S, Ueda T, Shibata H et al. Fibrinolysis in patients with acute promyelocytic leukemia and disseminated intravascular coagulation during heparin therapy. Cancer 1986; 58: 1736–1738.
32. Menell JS, Cesarman GM, Jacovina AT et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340: 994–1004.
33. Brower MS, Harpel PC. Proteolytic cleavage and inactivation of α2–plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 1982; 257: 9849–9854.
34. Kawai Y, Watanabe K, Kizaki M et al. Rapid improvement of coagulopathy by all‑trans retinoic acid in acute promyelocytic leukemia. Am J Hematol 1994; 46: 184–188.
35. Zokas L, Glenney JR Jr. The calpactin light chain is tightly linked to the cytoskeletal form of calpactin I: studies using monoclonal antibodies to calpactin subunits. J Cell Biol 1987; 105: 2111–2121.
36. Levin MD, Betjes MG, V d Kwast TH et al. Acute renal cortex necrosis caused by arterial thrombosis during treatment for acute promyelocytic leukemia. Haematologica 2003; 88: ECR21.
37. Hashimoto S, Koike T, Tatewaki W et al. Fatal thromboembolism in acute promyelocytic leukemia during all‑trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 1994; 8: 1113–1115.
38. Tsukada N, Wada K, Aoki S et al. Induction therapy with all‑trans retinoic acid for acute promyelocytic leukemia: a clinical study of 10 cases, including a fatal case with thromboembolism. Intern Med 1996; 35: 10–14.
39. Avvisati G, Lo Coco F, Diverio D et al. AIDA (all‑trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390–1398.
40. Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005; 105: 3019–3025.
41. Sanz MA, Lo Coco F. Standard practice and contoversial issues in front‑line therapy of acute promyelocytic leukemia. Haematologica 2005; 90: 840–845.
42. Adès L, Chevret S, Raffoux E et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24: 5703–5710.
43. Barbui T, Finazzi G, Falanga A. The impact of all‑trans‑retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91: 3093–3102.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2008 Číslo 7-8
Najčítanejšie v tomto čísle
- An urgency in hematology: acute promyelocytic leukemia – principles of diagnosis
- Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia
- Brief case reports illustrate various initial courses in acute promyelocytic leukemia
- Leukemogenesis and therapy of acute promyelocytic leukemia: from the worse to the most favorable subtype of acute myeloid leukemia